CDT Equity (CDT) Operating Expenses (2022 - 2026)
CDT Equity's (CDT) quarterly Operating Expenses came in at $3.7 million in Q1 2026, up 1.11% YoY from $3.6 million in Q1 2025, and down 82.72% on a QoQ basis from $21.2 million in Q4 2025.
CDT Equity (CDT) Operating Expenses (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Operating Expenses data on file, last reported at $3.7 million in Q1 2026.
- Quarterly Operating Expenses rose 1.11% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.8 million (up 128.84% YoY) and the FY2025 annual result came in at $36.8 million, up 138.39% from the prior year.
- Operating Expenses fell to $3.7 million in Q1 2026, from $21.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $21.2 million in Q4 2025 to a low of $243718.0 in Q1 2022.
- A 5-year average of $3.8 million and a median of $3.0 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses slumped 53.91% — and 2024, when it jumped 1251.4%.
- Tracing CDT's Operating Expenses over 5 years: stood at $1.7 million in 2022, then jumped by 45.1% to $2.4 million in 2023, then surged by 44.63% to $3.5 million in 2024, then soared by 502.22% to $21.2 million in 2025, then slumped by 82.72% to $3.7 million in 2026.
- The last three Operating Expenses figures came in at $3.7 million (Q1 2026), $21.2 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 541.02 Mn |
| 10 | CDT Equity | 1.63 Mn | 1.63 Mn | - | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.66 Mn |
| Dec 31, 2025 | 21.16 Mn |
| Sep 30, 2025 | 7.03 Mn |
| Jun 30, 2025 | 4.95 Mn |
| Mar 31, 2025 | 3.62 Mn |
| Dec 31, 2024 | 3.51 Mn |
| Sep 30, 2024 | 5.81 Mn |
| Jun 30, 2024 | 3.14 Mn |
| Mar 31, 2024 | 2.96 Mn |
| Dec 31, 2023 | 2.43 Mn |
| Sep 30, 2023 | 430,000.00 |
| Jun 30, 2023 | 888,000.00 |
| Mar 31, 2023 | 1.52 Mn |
| Dec 31, 2022 | 1.67 Mn |
| Sep 30, 2022 | 933,000.00 |
| Jun 30, 2022 | 249,420.00 |
| Mar 31, 2022 | 243,718.00 |